Although much attention has been devoted to the latter aspect of the AD phenotype, the ability of EVOO and its derivatives to potentially modulate also phosphorylation and aggregation of tau protein so far has been evaluated only using in vitro systems (Daccache et al., 2011; Li et al., 2009). This evidence concerns the gene MAPT and Alzheimer disease.